The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Compugen
Stock and Other Ownership Interests - Compugen
COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).
 
Daniel A. Vaena
Honoraria - HMP
Consulting or Advisory Role - Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Eisai; EMD Serono; Exelixis; Genomic Health; Immunomedics; natera; Seagen
Research Funding - Aeglea Biotherapeutics (Inst); AstraZeneca (Inst); BioClin Therapeutics (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Compugen (Inst); Compugen (Inst); incyte (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); OBI Pharma (Inst); Peloton Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst)
 
Gini F. Fleming
Honoraria - Curio Science
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Abbvie (Inst); Astex Pharmaceuticals (Inst); Compugen (Inst); Corcept Therapeutics (Inst); Eisai (Inst); Forty Seven (Inst); Genentech (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Leap Therapeutics (Inst); Merck (Inst); Plexxikon (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sermonix Pharmaceuticals (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
(OPTIONAL) Uncompensated Relationships - TTC Oncology
 
Bartosz Chmielowski
Consulting or Advisory Role - Deciphera; Epizyme; Genentech; IDEAYA Biosciences; Iovance Biotherapeutics; Nektar; OncoSec; Sanofi
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Advenchen Laboratories (Inst); Aeglea Biotherapeutics (Inst); Array BioPharma (Inst); Ascentage Pharma (Inst); Atreca (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); IDEAYA Biosciences (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Neon Therapeutics (Inst); Novartis (Inst); PACT Pharma (Inst); RAPT Therapeutics (Inst); Replimune (Inst); Rgenix (Inst); Tolero Pharmaceuticals (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Deciphera; Epizyme; Regeneron
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Alexion Pharmaceuticals; Amgen; Biogen; Bristol-Myers Squibb; Lilly; Medtronic; Merck; Pfizer; Regeneron
Research Funding - Alexo Therapeutics (Inst); Alpine Immune Sciences (Inst); Arrys Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Epizyme (Inst); Exelixis (Inst); Forty Seven (Inst); Genmab (Inst); GlaxoSmithKline/Tesaro (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); KLUS Pharma (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); PureTech (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Shattuck Labs (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Erika P. Hamilton
Consulting or Advisory Role - Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Akeso Biopharma (Inst); Amgen (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Polyphor (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Ryan J. Sullivan
Consulting or Advisory Role - alkermes; Asana Biosciences; AstraZeneca; Bristol-Myers Squibb; Eisai; Iovance Biotherapeutics; Merck; Novartis; OncoSec; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Viralytics (Inst)
 
Dale Randall Shepard
Consulting or Advisory Role - Sanofi
Speakers' Bureau - Celgene; Genentech/Roche
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Corvus Pharmaceuticals (Inst); Genentech/Roche (Inst); GITR (Inst); Harpoon therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Nektar (Inst); PsiOxus Therapeutics (Inst); Shanghai Miracogen Inc. (Inst); VBL Therapeutics (Inst)
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Bayer (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Genentech/Roche (I); Merck; MERCK (I); Novartis; Seagen; Silverback Therapeutics
Research Funding - Abbvie (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Bolt Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Ionova (Inst); Klus Pharma (Inst); Lilly (Inst); Livzon (Inst); Merck (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Plexxikon (Inst); Sanofi (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)
 
Adam ElNaggar
Consulting or Advisory Role - Abbvie; AstraZeneca; Clovis Oncology; Merck; Tesaro/GSK
Research Funding - AstraZeneca; Caris Life Sciences; Tesaro/GSK
 
Adeboye H. Adewoye
Employment - Compugen
Leadership - Compugen
Stock and Other Ownership Interests - Compugen
Research Funding - Compugen
Patents, Royalties, Other Intellectual Property - Compugen
 
Robina Smith
No Relationships to Disclose
 
Emerson A. Lim
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ecaterina Elena Dumbrava
Consulting or Advisory Role - Bolt Biotherapeutics
 
Drew W. Rasco
Research Funding - Abbvie (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Incyte (Inst); Macrogenics (Inst); Merck (Inst); PureTech (Inst); Seven and Eight Biopharmaceuticals (Inst); Takeda (Inst)